X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Natoli NP-RD30 Included at Diosna ProcessLab

Content Team by Content Team
21st September 2020
in Drug Development, News
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
The Diosna Dierks & Söhne GmbH recently opened the “Diosna ProcessLab” located in Osnabrück, Germany. The lab, which was completed in April 2020, offers research and formulation trials as well as virtual and in-person training classes. It offers an overview of the different system options and various possibilities for experimental implementation.

The NP-RD30 Rotary Tablet Press

One of the systems included in the Diosna ProcessLab is the Natoli NP-RD30, which is designed to help solve formulation and scale-up challenges. The multi-functional rotary tablet press replicates the design and functionality of a full-scale production press with the analytical capabilities of an R&D machine.

The NP-RD30 helps to get products to market faster with the data acquisition, analysis, and scalability features included in its user-friendly interface. The NP-RD30 is 21 CFR Part 11 compliant. It comes with an intuitive 21” HMI touchscreen and USB port for data transfer. Rolling casters allow for easy mobility of the machine. The NP-RD30 is equipped with an integrated duel vacuum system, a built-in calibration tool, upper and lower punch seals, powder recirculation system, and self-adjusting lower punch retainers with an exclusive push button feature.

Efficient and Dependable

An optimized fast-fill cam design creates a vacuum to assist in die filling for more consistent tablet weights. The NP-RD30 is designed with same diameter pre- and main compression rollers, independent overload, ejection, and take-off force monitoring. While designed to meet the needs of research and development, the NP-RD30 can also be used as a small batch production press with efficient and dependable standard batch reporting.

The NP-RD30 will be used to help enable the complete production of tablets for seminars, training, and more. The tablet press completes the manufacturing process chain at the Diosna ProcessLab that starts with powder mixing, granulation, final blending, tableting (completed with the NP-RD30), and finally, coating of the tablets. Customers who perform formulation trials at Diosna ProcessLab, are able to compress the granules to tablets, getting the opportunity to handle and analyze the quality of the final tablet with all its physical and chemical characteristics.

The first seminar in the new Diosna ProcessLab, “PTS-Seminar: Intensive Training Wet Granulation,” is planned for October 28-29, 2020 depending on availability of the Diosna ProcessLab due to current global circumstances. The number of attendees has been reduced to provide a safe environment in accordance with the Good Manufacturing Practice (GMP) standards with the World Health Organization (WHO). The Diosna ProcessLab and the equipment was also built according to GMP standards.

Previous Post

OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

Next Post

DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In